Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reminyl impaired cognitive function?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

J&J's Alzheimer's agent Reminyl (galantamine) yielded a higher mortality rate versus placebo in two studies in mild cognitive impairment, prompting a review by FDA and foreign health authorities, J&J says Jan. 21. Of the approximately 2,000 patients in the GAL-INT-11 and GAL-INT-18 studies, "20 deaths due to various causes were reported during the double-blind portion of the two pivotal studies, with 15 occurring in subjects randomized to galantamine and five occurring in patients receiving placebo," the company reports. Neither trial showed efficacy in mild cognitive impairment - J&J is no longer pursuing an indication in the condition...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002800

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel